Wrn helicase inhibitor

A compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof:

• wherein,
• represents a single bond or a double bond;
• X and Y are each independently selected from CH and N, and at least one of X and Y is N;
• R1 is selected from
• alternatively, R1 is selected from
• and the R1 is optionally substituted with 1 or 2 Rx;
• R2 is selected from H, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkylthio and C3-6 cycloalkyl;
• R3 is independently selected from H, halogen, CN, C1-6 alkyl, C1-6 haloalkyl and C3-6 cycloalkyl;
• or two R3 on the same or different carbon atoms are connected to form a 3- to 6-membered spiro or bridged ring;
• R4 is independently selected from H, halogen, CN, SF5, —SCF3, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylthio, C3-6 cycloalkyl and 4- to 10-membered heterocyclyl;
• Ring A and the benzene ring to which it is connected together form a fused ring, and Ring A is selected from 5- to 6-membered heteroaryl and 5- to 7-membered heterocyclyl;
• R5 is selected from H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkylthio and C3-6 cycloalkyl;
• Rx is selected from H, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, CN, NH2, —C(O)Ra, —C(O)ORa, —(CH2)p—ORa, —P(O)—(Ra)2 and —S(O)2—Ra;
• Ra is selected from H, C1-6 alkyl and C3-6 cycloalkyl;
• m is selected from 0, 1, 2 and 3;
• n is selected from 0, 1 and 2;
• p is selected from 0, 1 and 2.